Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Non-cash Items (2022 - 2025)

Axsome Therapeutics' Non-cash Items history spans 4 years, with the latest figure at $919114.0 for Q4 2025.

  • For Q4 2025, Non-cash Items fell 99.37% year-over-year to $919114.0; the TTM value through Dec 2025 reached $919114.0, down 99.37%, while the annual FY2025 figure was $919114.0, 99.37% down from the prior year.
  • Non-cash Items for Q4 2025 was $919114.0 at Axsome Therapeutics, down from $112.6 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $177.5 million in Q2 2024 and bottomed at $244068.0 in Q3 2023.
  • The 4-year median for Non-cash Items is $101.9 million (2022), against an average of $89.8 million.
  • The largest annual shift saw Non-cash Items crashed 99.75% in 2023 before it surged 66936.53% in 2024.
  • A 4-year view of Non-cash Items shows it stood at $95.7 million in 2022, then plummeted by 99.66% to $323159.0 in 2023, then surged by 45264.67% to $146.6 million in 2024, then tumbled by 99.37% to $919114.0 in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Non-cash Items are $919114.0 (Q4 2025), $112.6 million (Q3 2025), and $133.8 million (Q2 2025).